Since its emergence in 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread to become the major health issue of the past two years. But it’s also a research field of interest for many researchers. With the latest findings, SARS-CoV-2 has more to reveal… including one related to ADCC.

Developed by Epicypher and available in Europe through tebu-bio, CUTANA CUT&RUN and its sister technology CUT&TAG are quickly becoming the preferred approaches for Chromatin Mapping experiments over the classical method ChiP-Seq. To supplement these advances, EpiCypher is also leading the way for the validation of highly specific antibodies to histone PTMs for chromatin profiling assays. Let’s see how these new antibodies are validated.

Monoclonal antibodies (mAbs) are used as immunotherapeutics to treat cancer and other diseases, and either aim to induce target cell destruction or immune cell activation. After binding to their cognate antigens, mAbs engage Fc gamma receptor  (FcγR), localised on the surface of the Immune cells, and identified by many research groups as regulator of mAbs activity. To help researchers working on immunotherapeutic mAbs development, BPS Bioscience have developed a new CHO K1 cell line stably expressing full length human FcGR2B.

Enteroviruses are common human viruses causing rather mild symptoms. However many different species and serotypes (incl. Echoviruses, Polioviruses, Coxsackieviruses A and B) can cause serious illness (like EV71 & Coxsackie A16 with Hand Foot and Mouth Disease or EV70 with acute haemorrhagic conjunctivitis, neurologic dysfunction and permanent polio-like paralysis).

In this brief post, you will discover recent Antigen & Antibody developments made in this field by Meridian Life Sciences.